A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy
Sponsor: argenx • ClinicalTrials.gov ID: NCT07610564
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The main purpose of the study is to evaluate empasiprubart use in adults living with Multifocal Motor Neuropathy (MMN). The researchers will evaluate the effect of empasiprubart on the thickness of the nerves, muscle strength, movement, and on the potential improvement of grip strength of the participants in handling objects. The study consists of an open-label treatment period where all participants will receive empasiprubart intravenously (IV). After the last dose of empasiprubart participants will enter a safety follow-up period for up to 15 months. The total study duration for each participant will be approximately 29 months. More information can be found here: clinicaltrials.argenx.com/empasound
Interventions
-
Empasiprubart IV
(Biological)
Intravenous infusions of empasiprubart
Eligibility criteria
Conditions
Locations
- Pineo Medical Ecosystem — Tbilisi, K'alak'i T'bilisi, Georgia
- Aversi Clinic LTD — Tbilisi, Georgia
- Jo Ann Medical Center — Tbilisi, Georgia
- S. Khechinashvili University Clinic, Ltd. — Tbilisi, Georgia
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record